Tumor Biology

, Volume 37, Issue 7, pp 8901–8907 | Cite as

Comparison of efficacy and safety of three different chemotherapy regimens delivered with concomitant radiotherapy in inoperable stage III non-small cell lung cancer patients

  • Melike Ozcelik
  • Taner Korkmaz
  • Hatice Odabas
  • Cengiz Gemici
  • Ozlem Ercelep
  • Sinemis Yuksel
  • Aslihan Guven Mert
  • Heves Surmeli
  • Deniz Isik
  • Dincer Aydin
  • Mesut Seker
  • Alparslan Mayadagli
  • Pınar Ozdemir
  • Mehmet Aliustaoglu
  • Mahmut Gumus
Original Article

Abstract

Concomitant administration of chemotherapy and radiotherapy is currently recognized as the standard of treatment in locally advanced inoperable non-small cell lung cancer (NSCLC). Our study aimed to compare the efficacy and toxicities of three different chemotherapy regimens delivered concurrently with radiotherapy. We retrospectively reviewed the clinical records of patients who received the PE (cisplatin, 50 mg/m2, on days 1, 8, 29, and 36 plus etoposide, 50 mg/m2, on days 1 to 5 and 29 to 33), PD (docetaxel, 20 mg/m2, on day 1 plus cisplatin, 20 mg/m2, on day 1, every week), and PC (carboplatin, AUC 2 plus paclitaxel, 45 mg/m2, on day 1, every week) regimens concurrently with radiotherapy. A total of 227 patients were evaluated in the study. Median follow-up time was 13 months (2–101). There were 27 females (11.9 %) and 200 males (88.1 %) with a median age of 61 (38–82) years. The PD group had higher rates of esophagitis, mucositis, and anemia (p < 0.05). The PC group had higher rates of neuropathy (p = 0.000). The progression-free survival (PFS) time was 10 months for patients in the PC group, 15 months for patients in the PD group, and 21 months for the PE group (p = 0.010). Patients in the PC group had a median overall survival time of 23 months, those in the PD group 27 months, and those in the PE group 36 months (p = 0.098). Combination of cisplatin-etoposide with radiotherapy led to a more favorable outcome compared with the other two regimens. It shows generally manageable toxicity profile and compliance to treatment is noticeable.

Keywords

Concurrent chemoradiation Non-small cell lung cancer Stage III 

Notes

Acknowledgments

This manuscript presented as a poster in ESMO 2014 in Madrid.

Compliance with ethical standards

Conflicts of interest

None

References

  1. 1.
    Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin. 2012;62:10–29.CrossRefPubMedGoogle Scholar
  2. 2.
    García-Campelo R, Bernabé R, Cobo M, Corral J, Coves J, Dómine M, et al. SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015. Clin Transl Oncol. 2015;17:1020–9.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Adamowicz K, Goszczynska-Matysiak E. Combining systemic therapies with radiation in non small cell lung cancer. Klin Onkol. 2015;28:321–31.CrossRefPubMedGoogle Scholar
  4. 4.
    Vokes EE, Senan S, Treat JA, Iscoe NA. PROCLAIM: a phase III study of pemetrexed, cisplatin, and radiation therapy followed by consolidation pemetrexed versus etoposide, cisplatin, and radiation therapy followed by consolidation cytotoxic chemotherapy of choice in locally advanced stage III non-small-cell lung cancer of other than predominantly squamous cell. Lung Cancer. 2009;10:193–8.CrossRefGoogle Scholar
  5. 5.
    Sause W, Kolesar P, Taylor IV S, Johnson D, Livingston R, Komaki R, et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest. 2000;117:358–64.CrossRefPubMedGoogle Scholar
  6. 6.
    Reboul FL. Radiotherapy and chemotherapy in locally advanced non-small cell lung cancer: preclinical and early clinical data. Hematol Oncol Clin North Am. 2004;18:41–53.CrossRefPubMedGoogle Scholar
  7. 7.
    Auperin A, Le Pechoux C, Rolland E, Curran WJ, Furuse K, Fournel P, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010;28:2181–90.CrossRefPubMedGoogle Scholar
  8. 8.
    Curran Jr WJ, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, et al. Sequential vs. concurrent chemoradiation for stage III non small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011;103:1452–60.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–55.CrossRefPubMedGoogle Scholar
  10. 10.
    National Cancer Institute. National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE). v4.0. Bethesda, MD: Cancer Therapy Evaluation Program, 2011.Google Scholar
  11. 11.
    Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.CrossRefPubMedGoogle Scholar
  12. 12.
    Kelly K, Chansky K, Gaspar LE, Albain KS, Jett J, Ung YC, et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer. SWOG S0023. J Clin Oncol. 2008;26:2450–6.CrossRefPubMedGoogle Scholar
  13. 13.
    Hanna N, Neubauer M, Yiannoutsos C, McGarry R, Arseneau J, Ansari R, et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: The Hoosier Oncology Group and U.S. Oncology. J Clin Oncol. 2008;26:5755–60.CrossRefPubMedGoogle Scholar
  14. 14.
    Vokes EE, Herndon 2nd JE, Kelley MJ, Cicchetti MG, Ramnath N, Neill H, et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer. Cancer and Leukemia Group B. J Clin Oncol. 2007;25:1698–704.CrossRefPubMedGoogle Scholar
  15. 15.
    Belani CP, Choy H, Bonomi P, Scott C, Travis P, Haluschak J, et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer. A randomized phase II locally advanced multi-modality protocol. J Clin Oncol. 2005;23:5883–91.CrossRefPubMedGoogle Scholar
  16. 16.
    Segawa Y, Ueoka H, Kiura K, Tabata M, Kamei H, Takigawa N, et al. A phase I/II study of docetaxel and cisplatin with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer. Proc Am Soc Clin Oncol. 2000;19:508a.Google Scholar
  17. 17.
    Wu H-G, Bang Y-J, Choi EK, Ahn YC, Kim YW, Lim TH, et al. Phase I study of weekly docetaxel and cisplatin concurrent with thoracic radiotherapy in stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2002;52:75–80.CrossRefPubMedGoogle Scholar
  18. 18.
    Belderbos J, Uitterhoeve L, van Zandwijk N, Belderbos H, Rodrigus P, van de Vaart P, et al. Randomized trial of sequential versus concurrent chemoradiotherapy in patients with inoperable non-small-cell lung cancer (EORTC 08972–22973). Eur J Cancer. 2007;43:114–21.CrossRefPubMedGoogle Scholar
  19. 19.
    Xu Y, Ma S, Ji Y, Sun X, Jiang H, Chen J, et al. Concomitant chemoradiotherapy using pemetrexed and carboplatin for unresectable stage III non-small cell lung cancer (NSCLC): preliminary results of a phase II study. Lung Cancer. 2011;72:327–32.CrossRefPubMedGoogle Scholar
  20. 20.
    Albain KS, Crowley JJ, Turrisi 3rd AT, Gandara DR, Farrar WB, Clark JI, et al. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol. 2002;20:3454–60.CrossRefPubMedGoogle Scholar
  21. 21.
    Segawa Y, Kiura K, Takigawa N, Kamei H, Harita S, Hiraki S, et al. Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non small cell lung cancer: OLCSG 0007. J Clin Oncol. 2010;28:3299–306.CrossRefPubMedGoogle Scholar
  22. 22.
    Yamamoto N, Nakagawa K, Nishimura Y, Tsujino K, Satouchi M, Kudo S, et al. Phase III study comparing second and third generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non small cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105. J Clin Oncol. 2010;28:3739–45.CrossRefPubMedGoogle Scholar
  23. 23.
    Wang L, Wu S, Ou G, Bi N, Li W, Ren H, et al. Randomized phase II study of concurrent cisplatin/etoposide or paclitaxel/carboplatin and thoracic radiotherapy in patients with stage III non-small cell lung cancer. Lung Cancer. 2012;77:89–96.CrossRefPubMedGoogle Scholar
  24. 24.
    Liew MS, Sia J, Starmans MH, Tafreshi A, Harris S, Feigen M, et al. Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage III non-small-cell lung cancer. Cancer Med. 2013;2:916–24.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Crvenkova S, Pesevska M. Important prognostic factors for the long-term survival in non-small cell lung cancer patients treated with combination of chemotherapy and conformal radiotherapy. J BUON. 2015;20:775–81.PubMedGoogle Scholar
  26. 26.
    Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest. 2002;122:1037–57.CrossRefPubMedGoogle Scholar
  27. 27.
    Kim S, Kim M, Choi E. Induction chemotherapy followed by concurrent chemoradiotherapy (CCRT) versus CCRT alone for unresectable stage III non-small-cell lung cancer: randomized phase III trial. J Clin Oncol. 2007;25:391s.Google Scholar
  28. 28.
    Gandara DR, Chansky K, Albain KS, Leigh BR, Gaspar LE, Lara Jr PN, et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol. 2003;21:2004–10.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  • Melike Ozcelik
    • 1
  • Taner Korkmaz
    • 1
  • Hatice Odabas
    • 1
  • Cengiz Gemici
    • 2
  • Ozlem Ercelep
    • 1
  • Sinemis Yuksel
    • 1
  • Aslihan Guven Mert
    • 1
  • Heves Surmeli
    • 1
  • Deniz Isik
    • 1
  • Dincer Aydin
    • 1
  • Mesut Seker
    • 3
  • Alparslan Mayadagli
    • 3
  • Pınar Ozdemir
    • 1
  • Mehmet Aliustaoglu
    • 1
  • Mahmut Gumus
    • 3
  1. 1.Department of Medical OncologyKartal Dr. Lutfi Kirdar Education and Research HospitalIstanbulTurkey
  2. 2.Department of Radiation OncologyKartal Dr. Lutfi Kirdar Education and Research HospitalIstanbulTurkey
  3. 3.Department of Medical OncologyBezmialem Vakif University School of MedicineIstanbulTurkey

Personalised recommendations